Here, we report the generation and the functional characterization of a novel EGFR-CD16 bispecific VHH that, in in vitro and ex vivo studies, enhances NK cell function to improve tumor control through simultaneous targeting of CD16 on effector NK cells and EGFR on epithelial cancers. The gene discussed is FCGR3A; the disease is neoplasm.